**Name of Journal:** *World Journal of Stem Cells*

**Manuscript NO:** 41507

**Manuscript Type:** REVIEW

**Cytokines in adipose-derived mesenchymal stem cells promote the healing of liver disease**

Nahar S *et al.* Protein factors in cirrhosis treatment

Saifun Nahar, Yoshiki Nakashima, Chika Miyagi-Shiohira, Takao Kinjo, Zensei Toyoda, Naoya Kobayashi, Issei Saitoh, Masami Watanabe, Hirofumi Noguchi, Jiro Fujita

**Saifun Nahar, Jiro Fujita,** Department of Infectious, Respiratory, and Digestive Medicine, Graduate School of Medicine, University of the Ryukyus, Okinawa 903-0215, Japan

**Yoshiki Nakashima, Chika Miyagi-Shiohira, Hirofumi Noguchi,** Department of Regenerative Medicine, Graduate School of Medicine, University of the Ryukyus, Okinawa 903-0215, Japan

**Takao Kinjo, Zensei Toyoda,** Department of Basic Laboratory Sciences, School of Health Sciences in the Faculty of Medicine, University of the Ryukyus, Okinawa 903-0215, Japan

**Naoya Kobayashi,** Okayama Saidaiji Hospital, Okayama 704-8192, Japan

**Issei Saitoh,** Division of Pediatric Dentistry, Graduate School of Medical and Dental Science, Niigata University, Niigata 951-8514, Japan

**Masami Watanabe,** Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558, Japan

**ORCID number:** Saifun Nahar (0000-0003-4696-617X); Yoshiki Nakashima (0000-0003-1827-7609); Chika Miyagi-Shiohira (0000-0003-0061-585X); Takao Kinjo (0000-0002-5316-4071); Zensei Toyoda(0000-0002-2667-0446); Naoya Kobayashi (0000-0003-2638-3102); Issei Saitoh (0000-0002-7451-0666); Masami Watanabe (0000-0003-1268-1029); Hirofumi Noguchi (0000-0002-0880-6805); Jiro Fujita (0000-0003-3423-8343).

**Author contributions:** Nahar S, Nakashima Y, Miyagi-Shiohira C and Noguchi H designed and conducted the study; Nahar S, Nakashima Y, Miyagi-Shiohira C, Kinjo T, ToyodaZ and Noguchi H collected, analysed and interpreted the data; Kinjo T, Kobayashi N, Saitoh I, Watanabe M and Fujita J provided the materials; drafting of the manuscript, Nahar S, Nakashima Y and Noguchi H drafted, revised the manuscript; Nahar S, Nakashima Y, Miyagi-Shiohira C, Kinjo T, ToyodaZ, Kobayashi N, Saitoh I, Watanabe M, Noguchi H and Fujita J approved the final version of the manuscript; Nahar S takes responsibility for the integrity of all of the data analyses.

**Conflict-of-interest statement:** Authors of this manuscript have no conflicts of interest to disclose.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

**Manuscript source:** Invited manuscript

**Correspondence to: Hirofumi Noguchi, MD, PhD, Professor,** Department of Regenerative Medicine, Graduate School of Medicine, University of the Ryukyus, 207 Uehara, Nishihara, Okinawa 903-0215, Japan. [noguchih@med.u-ryukyu.ac.jp](mailto:noguchih@med.u-ryukyu.ac.jp)

**Telephone:** +81-98-8951696

**Fax:** +81-98-8951684

**Received:** August 10, 2018

**Peer-review started:** August 13, 2018

**First decision:** August 24, 2018

**Revised:** September 7, 2018

**Accepted:** October 11, 2018

**Article in press:**

**Published online:**

**Abstract**

Adipose-derived mesenchymal stem cells (ADSCs) are a treatment cell source for patients with chronic liver injury. ADSCs are characterized by being harvested from the patient's own subcutaneous adipose tissue, a high cell yield (*i.e.*, reduced immune rejection response), accumulation at a disease nidus, suppression of excessive immune response, production of various growth factors and cytokines, angiogenic effects, anti-apoptotic effects, and control of immune cells via cell-cell interaction. We previously showed that conditioned medium of ADSCs promoted hepatocyte proliferation and improved the liver function in a mouse model of acute liver failure. Furthermore, as found by many other groups, the administration of ADSCs improved liver tissue fibrosis in a mouse model of liver cirrhosis. A comprehensive protein expression analysis by liquid chromatography with tandem mass spectrometry showed that the various cytokines and chemokines produced by ADSCs promote the healing of liver disease. In this review, we examine the ability of expressed protein components of ADSCs to promote healing in cell therapy for liver disease. Previous studies demonstrated that ADSCs are a treatment cell source for patients with chronic liver injury. This review describes the various cytokines and chemokines produced by ADSCs that promote the healing of liver disease.

**Key words:** Adipose-derived mesenchymal stem cells; Cell transplantation therapy; cytokine; Hepatocytes; Liquid chromatography with tandem mass spectrometry; Liver cirrhosis

**© The Author(s) 2018.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** We previously showed that conditioned medium of adipose-derived mesenchymal stem cells (ADSCs) promoted hepatocyte proliferation and improved the liver function in a mouse model of acute liver failure. Furthermore, as reported by many other groups, the administration of ADSCs improved liver tissue fibrosis in a mouse model of liver cirrhosis. A comprehensive protein expression analysis by liquid chromatography with tandem mass spectrometry showed that the various cytokines and chemokines produced by ADSCs have the ability to promote the healing of liver disease. In this review, we examine the ability of the expressed protein components of ADSCs to promote healing in cell therapy for liver disease.

Nahar S, Nakashima Y, Miyagi-Shiohira C, Kinjo T, Toyoda Z, Kobayashi N, Saitoh I, Watanabe M, Noguchi H, Fujita J. Protein factors in adipose-derived mesenchymal stem cell transplantation for liver cirrhosis. *World J Stem Cells* 2018; In press

**INTRODUCTION**

We and others have conducted clinical studies in patients with symptoms of autoimmune liver disease[1], hepatitis C[2,3], bacterial infection[4], acute liver failure liver[5], nonalcoholic fatty liver disease[6] and cirrhosis. We have also conducted translational research that bridges basic research using hematopoietic cells[7-14], hepatic stellate cells (HSCs)[15-18], embryonic stem cell-derived hepatocytes[19-22], bioartificial livers[23-26], animals[27-33] and clinical research in humans.

Thanks to their expected therapeutic efficacy, mesenchymal stem cells[34] are currently under clinical evaluation as a cell source for cell therapy in trials of regenerative medicine for a broad spectrum of diseases. Since adipose-derived mesenchymal stem cells (ADSCs)[35,36] are obtained from the patient's abdomen by liposuction, cell procurement is relatively easy (large numbers of cells can be obtained by minimally invasive treatment). ADSCs can avoid immune rejection if they are autografted[37-39]; however, similarly to other cell sources, they are subject to immune rejection if allogeneic or xeno cell transplantation is performed. Mesenchymal stem cells are used for medical treatment worldwide. Since ADSCs are not a mainstream therapeutic cell, we have been performing clinical studies of treatments using ADSCs. For this reason, cell therapy using ADSCs is now performed in many public and private hospitals worldwide. In this review, we examine the effects of ADSCs in cell therapy for liver diseases, focusing on the proteins secreted by ADSCs. We previously reported that the proteins expressed by human ADSCs cultured using Dulbecco's Modified Eagle's medium [10% fetal bovine serum (FBS)] and clinical-grade chemically-defined medium showed 98% similarity, demonstrating that the proteins expressed by ADSCs cultured in media for research and clinical use largely coincide[40,41]. However, using animal-derived components in the process of culturing cells for treatment is associated with a risk of transmitting pathogenic infections derived from animals (*e.g.*, bovine spongiform encephalopathy or swine fever). Furthermore, when animal-derived ingredients are used the risks and quality may vary in individual lots. Thus, the use of chemically defined media with recombinant protein is recommended for large-scale culture conditions, such as the manufacturing of therapeutic cells for industrial use. In this background, we use the medium containing FBS as the control medium for the cultivation of research cells, while chemically-defined media is the first choice for culturing therapeutic cells. In addition, we do not deny the option of using a supplement that uses infectious and highly safe virus-tested human serum as a raw material for culturing therapeutic cells.

Gene ontology (GO) facilitates[42,43] the development of a common vocabulary to describe biological concepts. Terms defined in GO are called GO terms (GO is a classification of biological phenomena that associates genes with their known [reported in the existing literature] biological role structured based on given criteria), which are divided into three categories: biological processes, cellular components, and molecular functions. The Gene Ontology Consortium (http://www.geneontology.org/) is a database of functional information that aims to describe biological phenomena in standardized terms. In recent years, liquid chromatography with tandem mass spectrometry (LC-MS/MS) has been used to perform a GO classification of comprehensive expression data using protein analysis software programs. Both a comprehensive expression analysis of proteins using LC-MS/MS and a protein GO analysis were performed according to methods that we reported previously[40,41,44].

In normal liver tissue, blood flows from the portal vein through the central veins, each of which supplies sufficient blood to the hepatocytes of a single hepatic lobule (Figure 1). The blood supply to hepatocytes remains sufficient in carbon tetrachloride (CCL4: 0.5 mL/kg)-administered acute liver failure model in mice[40,41]. Liver failure is a defined as a group of diseases associated with the development of symptoms such as jaundice, ascites, hepatic encephalopathy, bleeding tendency, or the like, due to a decrease in the number of hepatocytes or a decrease in their function. Acute liver failure is defined by the presence of necrosis and inflammation in normal liver tissue, with the period until the onset of symptoms of hepatic insufficiency being within 8 wk. Cases in which the onset of symptoms is 8–24 wk or > 24 wk are classified as delayed liver failure (late onset hepatic failure; LOHF) and chronic liver failure, respectively. The American Association for the Study of Liver Diseases published a position paper on acute liver failure in 2005 to unify the terms and disease concepts[45].

In contrast to this acute model, the preparation of the CCL4 (2.0 mL/kg)-administered cirrhosis model mouse requires more than 6 weeks. The liver tissue in this mouse model of liver cirrhosis shows a marked increase in the fiber component of the fibrous septa. This results in the separation of some lobules by fiber components, and the creation of pseudo-lobules. At the same time, the blood supply to the lobules decreases and liver cell necrosis occurs (Figure 2). Chronic liver injury also results in the differentiation of astrocytes into myofibroblastoid cells, in turn causing the pathogenesis of fibrotic liver injury[46]. Given this background, the factor most necessary for the improvement of acute liver failure symptoms is hepatocyte growth factor (HGF). In contrast, the most important factors for the improvement of the symptoms of chronic liver failure (*i.e.,* liver cirrhosis) are: (1) growth factors; (2) inhibition of the inflammation of hepatic stellate cells; and (3) angiogenic factors.

When the disordered repair process is delayed or inhibited after liver damage from drugs, trauma, inflammation, or other insults, liver regeneration is insufficient and hepatic failure develops. In hepatic tissue repair, in addition to growth factors that promote hepatocyte proliferation, angiogenic factors that promote hepatic microvascular remodeling are important. In addition, the extracellular matrix in the liver is mainly produced in hepatic stellate cells. The ability of hepatic stellate cells to produce extracellular matrix is low in the normal liver. However, in the fibrous liver, it is known that hepatic stellate cells are activated to differentiate into myofibroblasts and their ability to produce extracellular matrix markedly increases. Interleukin-6 (IL-6), tumor necrosis factor-α, HGF, and other factors secreted from HSCs, hepatic sinusoidal endothelial cells and Kupffer cells are thought to have the greatest influence on hepatocyte proliferation[47]. Angiogenesis is a physiological phenomenon in which a new blood vessel branch is branched from an existing blood vessel to construct a vascular network. The various factors involved in angiogenesis include fibroblast growth factor, vascular endothelial cell growth factor (VEGF), angiopoietin, and platelet derived growth factor (PDGF).

**GROWTH FACTORS IMPROVING THE SYMPTOMS OF LIVER CIRRHOSIS**

HGF acts as a HGF and metabolic regulator and promotes hepatocyte proliferation[48]. The hepatic development of the liver is the origin of the gut tube, which is formed by the accumulation of hematopoietic cells[49]. Thus, the idea that HGF expressed by hematopoietic cells promotes the regeneration of hepatocytes is plausible. Liver tissue regeneration using HGF may accordingly be considered a treatment method that reproduces the original development of the liver. HGF is expressed by both HSCs and ADSCs.

Our group previously investigated the clinical application of organ preservation solution[50-56]. We found that the expression level of HGF mRNA did not decrease in ADSCs, even when they were stored in preservation solution for 16 hours after separation from adipose tissue. In addition, we found no difference between the expression levels of HGF using glucose-free University of Wisconsin and glucose-containing (5.6 mmol/L) Hank’s Balanced Salt Solution. This result shows that the expression of HGF by ADSCs does not decrease after separation from adipose tissue. Moreover, the expression is not affected by the glucose concentration. In addition, the expression of VEGF showed a similar tendency. In short, ADSCs constantly express HGF and VEGF both *in vivo* and *in vitro*[57]. A recent theory suggests that the biliary tree functions as a source of liver and pancreatic stem cells and progenitor cells. VEGF is secreted by the biliary tree as a response to stress[58]. From these developmental perspectives, HGF and VEGF secreted by ADSCs appear to have a marked promoting effect on hepatocyte proliferation.

Our experiments showed that the administration of ADSC conditioned medium (CM) from a single vein rapidly promotes the cellular proliferation of mouse hepatocytes (Figure 3). The proteins associated with a growth function (GO analysis), identified by the presence of ADSC-CM, were Periostin (POSTN), P component (SAP), semaphorin 7A (SEM7A), and Inactive tyrosine-protein kinase 7[40, 41]. Periostin, which is encoded by the POSTIN gene, has been reported to be an extracellular factor that promotes hepatosteatosis[59,60]. Nevertheless, much remains unknown about proteins with the ability to promote the cellular proliferation of hepatocytes. For example, SAP, a protein that is expressed in hepatocytes and secreted into serum, is known to be involved in processes associated with immune regulation, such as the action of opsonins[61], but whether SAP is involved in the cellular proliferation of hepatocytes is unknown. Further, SEM7A is known to contribute to transforming growth factor (TGF)-β-mediated hepatic fibrosis[62], but whether it promotes hepatocyte cell proliferation is unknown. Future studies should therefore investigate whether the growth-associated proteins that are newly identified by GO analyses promote the cellular proliferation of hepatocytes in CCL4-induced liver impairment. What is certain is that HGF and VEGF secreted by ADSCs are among the key factors promoting the proliferation of hepatocytes.

**INFLAMMATION INHIBITOR OF HEPATIC STELLATE CELLS**

The Jun amino-terminal kinases (JNK) signaling pathway is involved in the activation of HSCs[63,64]. JNK1 plays a major role in the upregulation of the α-SMA expression in HSCs under the stress conditions induced by TGF-β during liver fibrosis[65]. We previously reported the clinical application of organ preservation solution with a JNK inhibitory peptide (11R-JNKI)[66-68] and 8R-sJNKI(-9)[69]. The design of these cell-permeable inhibitory peptides is not only significant for *in vivo* studies, but also for future attempts to design inhibitors of liver fibrosis for the clinical treatment of liver cirrhosis. In addition, we previously reported that Arg-Gly-Asp (RGD) peptide[70] and Rho-kinase inhibitor [71] suppresses liver fibrosis. Our experiments show that the administration of ADSCs (1 × 106 cells) from a total of three veins at a twice weekly interval rapidly improves the fibrosis of excessive mesenchyme around mouse hepatocytes (Figure 4). When ADSCs are administered via the mouse tail vein, they cause pulmonary embolism, which has a high probability of causing the death of the mouse. Our group developed a method to safely administer ADSCs using heparin[72]. The proteins associated with the immune system process (GO analysis) identified by the presence of ADSC-CM were FINC, CO1A2, CO1A1, CATB, TSP1, CFAH, GAS6, LEG1, PTX3, C1S, SEM7A, CLUS, G3P, PXDN, SRCRL, CD248, SPON2, ENPP2, CD109, CFAB, CATL1, MFAP5, MIF, CXCL5, ADA M9, and CATK (Table 1)[40,41]. Among these ADSC-secreted proteins, we found no studies reporting a relationship in the field of liver cirrhosis and hepatic stellate cells for FINC, CO1A2, CATB, CFAH, LEG1, C1S, SEM7A, CLUS, G3P, PXDN, SRCRL, SPON2, ENPP2, CD109, CFAB, CATL1, MFAP5, ADAM9, or CATK. It is expected that these proteins will be investigated in future studies.

Type I collagen and fibronectin are also reported to be components of hepatic fibrosis[73,74]. It is therefore unlikely that CO1A1 and CO1A2, which are secreted by ADSCs, suppress the excess activity of HSCs. Thrombospondin-1, a matricellular glycoprotein that is secreted by many cell types, modulates a variety of cellular functions by binding to extracellular proteins and/or cell surface receptors. Thrombospondin-1 might contribute to liver fibrosis not only as an activator of TGF-β, but also as a modulator of angiogenesis[75]. In the normal liver, growth arrest-specific gene 6 (Gas6) is mainly expressed in Kupffer cells. The expression of Gas6 increases in activated HSCs and macrophages after acute CCL4 administration [76]. Given that Gas6 and Axl are reported to be necessary for HSC activation[77], Gas6 secreted by ADSCs seems to have no effect in inhibiting the activity of HSCs. Pentraxin 3 (PTX3) is expressed and released by hematopoietic cells and stromal cells and is an essential component of innate immunity. IL-1 induces the production of PTX3 by Kupffer cells, endothelial cells and biliary duct epithelial cells. PTX3 is reported to be a biomarker of liver fibrosis in response to hepatic injury[78]. These reports indicate that PTX3 secreted by ADSCs is unlikely to suppress the activation of HSCs. CD248 (endosialin) is a stromal cell marker expressed on fibroblasts and pericytes. During liver injury, myofibroblasts are the main source of fibrotic matrix. Liver fibrosis was reported to be suppressed in CD248 knockout mice[79], suggesting that it is unlikely that CD248 secreted by ADSCs inhibits hepatic fibrosis. Macrophage migration inhibitory factor (MIF) is a pleiotropic inflammatory cytokine that has been implicated in various inflammatory diseases. MIF knockout mice were reported to have strongly increased fibrosis in a mouse model of chronic liver injury model. This phenomenon was accompanied by no change in the infiltration of intrahepatic immune cells. MIF has an anti-fibrotic effect on the liver *via* the MIF receptor (CD74). In addition, recombinant MIF protein has a similar anti-fibrotic effect[80]. These results indicate that MIF secreted by ADSCs is a major component in the suppression of liver fibrosis. CXCL5 is best known for its function as a neutrophil chemotactic factor and activator, with a molecular structure similar to that of IL-8 4, 5. CXCL5 is released from monocytes, neutrophils, epithelial cells, fibroblasts and smooth muscle during inflammation. Interestingly, CXCL5 has a proliferative effect on rat hepatocytes. The use of a neutralizing antibody of CXCL5 slowed the liver regeneration rate after partial hepatectomy[81]. The plasma CXCL5 levels are low in patients with chronic liver disease, and CXCL5 may be involved in the pathogenesis of chronic liver disease[82]. These results strongly indicate the possibility that CXCL5 secreted by ADSCs also promotes hepatocyte proliferation. These findings indicated that MIF is one of the components that suppress liver fibrosis among the ADSC-secreted proteins that we identified. In addition, CXCL5 was identified as a component that promotes hepatocyte proliferation. Of course, the function of these proteins has been previously reported. Table 1 shows 26 different proteins classified as immunomodulatory (GO analysis). The 18 proteins indicated by N/A have not been reported in the liver field, and further research into them is anticipated. Note that proteins that were not classified as immunomodulatory (by a GO analysis) may also have effects on the liver.

**ANGIOGENIC FACTORS**

EGF, VEGF and HGF, which are expressed by ADSCs, have a strong angiogenic effect on liver tissue[83-85]. Table 2 lists eight types of proteins [Plasminogen activator inhibitor 1 (PAI1), follistatin-related protein 1 (FSTL1), periostin (POSTN), matrix metalloproteinases 2 (MMP2), TSP1, metalloproteinase inhibitor 1 (TIMP1), Fibulins 3 (FBLN3) and Lactadherin (MFGM)] affecting angiogenesis from among 101 types of proteins secreted by ADSCs. PAI1 is a member of a family of proteins that inhibit plasminogen activators[86]. Although the binding of VEGF to vitronectin induces strong angiogenic signaling, this is inhibited by competitive binding to PAI1[87]. PAI1 secreted from ADSCs is therefore thought to inhibit angiogenesis by VEGF in liver tissue. FSTL1 is a secretory glycoprotein belonging to the follistatin and SPARC family. FSTL1 was reported to be highly expressed in fibrotic human liver tissue and activated HSCs[88]. FSTL1 has the effect of promoting the activity of HSCs. It is therefore unlikely that FSTL1 secreted by ADSCs affects angiogenesis. POSTN, an extracellular matrix (ECM) molecule of the fasciclin family, has roles in vascular cell differentiation and migration [89]. We therefore hypothesize that POSTN secreted by ADSCs may promote angiogenesis of the liver. MMPs are a family of over 24 zinc-dependent endopeptidases capable of degrading virtually any component of the ECM[90]. MMP2 plays an important role in the preservation of liver vascular homeostasis via its participation in the TGF-β activation process[91]. MMP2 secreted by ADSCs—and many other cell types—is therefore considered to be one of the main factors. TSP1 was reported to be increased in HSCs isolated from the liver in a mouse model of CCL4-induced cirrhosis. In liver samples of patients with alcohol cirrhosis and non-alcoholic steatohepatitis-related cirrhosis, TSP1 levels were reported to be increased[92]. It is thought that TSP1 expressed in the liver has the effect of promoting liver fibrosis. If so, it would be unlikely that TSP1 secreted by ADSCs promotes liver angiogenesis. TIMP1 is a widely expressed inhibitor of MMPs. Given that the inhibition of TIMP1 promotes angiogenesis by increasing cell motility during fibrovascular invasion[93], TIMP1 secreted by ADSCs may inhibit liver angiogenesis. FBLNs, a versatile family of extracellular matrix proteins, comprise a small family of widely expressed ECM proteins[94]. FBLN3 has been reported to be an angiogenesis antagonist that regulates cell morphology, growth, adhesion and motility[95]. It is therefore unlikely that FBLN3 secreted by ADSCs promotes liver angiogenesis. MFGM interacts with alphavbeta3 and alphaV-beta5 integrins and alters both VEGF-dependent Akt phosphorylation and neovascularization [96]. MFGM was reported to promote angiogenesis via enhanced PDGF-PDGFRβ signaling mediated by cross-talk of the integrin growth factor receptor[97]. Thus, MFGM secreted by ADSCs is considered to be one of the main components promoting liver angiogenesis. We recently reported that ADSCs strongly express MFGM and that human MFGM protected dopamine neurons in a rat model of Parkinson's disease model[98]. At the present stage, there are no reports on a therapeutic method for the disease-specific selection of therapeutic cells that reference to the list of protein components expressed by therapeutic stem cells.

Regarding cell therapy using ADSCs, we believe that excellent effects on immune response control by cell adhesion can be expected based on reports in the literature. For treatment with ADSC-CM, we used a method to concentrate ADSC-CM 20 times using a 10k filter. ADSC-CM is a liquid and has the advantage of being able to pass through both a 0.22-μm sterilizing filter and a 0.10-μm virus removal filter. We think that lowering the hurdles to cell therapy by taking advantage of the simple adjustment of the solution will contribute to a wide range of medical needs.

These results suggest that VEGF, HGF, EGF, MMP2, POSTN, and MFGM secreted by ADSCs promote hepatic angiogenesis. Among the 101 proteins expressed by ADSCs, we identified three proteins that promote angiogenesis from among eight proteins reported to be involved in angiogenesis. The further development of research into the 93 other proteins is expected.

A study of one-shot stem cell therapy reported the effects of bone marrow-derived mesenchymal stem cell treatment in 53 cirrhosis patients[99]. Although study period was sufficient to observe short-term symptomatic improvement over a period of days to weeks, it has been reported that there is no improvement in symptoms over the longer term (more than a few months). Although this study did not involve the use of ADSCs, it showed that stem cell treatment improves the symptoms of cirrhosis over the short term. However, it shows that one-shot stem cell therapy does not reset the pathological state of cirrhosis through natural healing power leading to recovery. In this paper, we reported that ADSC has three angiogenesis-inducing effects, which promoted the proliferation of hepatocytes, which suppressed the fibrosis of the liver tissue. We believe that medical stakeholders and patients will be more likely to challenge clinical studies of ADSCs in the treatment of cirrhosis. However, it is unlikely that ADSCs play a direct role in controlling all of the pathological conditions of cirrhosis in the body. Thus, we are of the opinion that cell therapy using ADSCs and treatment using ADSC-CM will be useful as supplementary treatments.

**CONCLUSION**

The factors necessary for improvement of the symptoms of chronic liver failure (i.e. liver cirrhosis) are: (1) growth factors; (2) inhibitors of hepatic stellate cell inflammation; and (3) angiogenic factors. (1) It is certain that ADSC-secreted HGF and VEGF are among the factors that promote the proliferation of hepatocytes. In addition, CXCL5 was identified as a component that promotes hepatocyte proliferation; (2) MIF, which was one of the ADSC-secreted proteins that we identified that suppressed liver fibrosis; and finally (3) ASDC-secreted VEGF, HGF, EGF, MMP2, POSTN and MFGM are factors that promote hepatic angiogenesis. It seems that the therapeutic effect on the symptoms of cirrhosis is based on ADSC-secreted growth factors, anti-inflammatory effects on stellate cells, and the anti-fibrotic and angiogenic effects of ADSC-secreted proteins.

**ACKNOWLEDGEMENTS**

We thank Naomi Kakazu (University of the Ryukyus) for clerical assistance and Maki Higa, Yuki Kawahira and Saori Adaniya (University of the Ryukyus) for providing technical support.

**REFERENCES**

1 **Aoyama H**, Hirata T, Sakugawa H, Watanabe T, Miyagi S, Maeshiro T, Chinen T, Kawane M, Zaha O, Nakayoshi T, Kinjo F, Fujita J. An inverse relationship between autoimmune liver diseases and Strongyloides stercoralis infection. *Am J Trop Med Hyg* 2007; **76**: 972-976 [PMID: 17488925 DOI: 10.4269/ajtmh.2007.76.972]

2 **Hoshino K**, Sugiyama M, Date T, Maruwaka S, Arakaki S, Shibata D, Maeshiro T, Hokama A, Sakugawa H, Kanto T, Fujita J, Mizokami M. Phylogenetic and phylodynamic analyses of hepatitis C virus subtype 1a in Okinawa, Japan. *J Viral Hepat* 2018; **25**: 976-985 [PMID: 29577516 DOI: 10.1111/jvh.12898]

3 **Maeshiro T**, Arakaki S, Watanabe T, Aoyama H, Shiroma J, Yamashiro T, Hirata T, Hokama A, Kinjo F, Nakayoshi T, Nakayoshi T, Mizokami M, Fujita J, Sakugawa H. Different natural courses of chronic hepatitis B with genotypes B and C after the fourth decade of life. *World J Gastroenterol* 2007; **13**: 4560-4565 [PMID: 17729406 DOI: 10.3748/wjg.v13.i34.4560]

4 **Hibiya K**, Utsunomiya K, Yoshida T, Toma S, Higa F, Tateyama M, Fujita J. Pathogenesis of systemic Mycobacterium avium infection in pigs through histological analysis of hepatic lesions. *Can J Vet Res* 2010; **74**: 252-257 [PMID: 21197224]

5 **Tanaka K**, Kobayashi N, Gutierrez AS, Rivas-Carrillo JD, Navarro-Alvarez N, Chen Y, Narushima M, Miki A, Okitsu T, Noguchi H, Tanaka N. Prolonged survival of mice with acute liver failure with transplantation of monkey hepatocytes cultured with an antiapoptotic pentapeptide V5. *Transplantation* 2006; **81**: 427-437 [PMID: 16477231 DOI: 10.1097/01.tp.0000188693.48882.18]

6 **Obika M**, Noguchi H. Diagnosis and evaluation of nonalcoholic fatty liver disease. *Exp Diabetes Res* 2012; **2012**: 145754 [PMID: 22110476 DOI: 10.1155/2012/145754]

7 **Kobayashi N**, Noguchi H, Westerman KA, Watanabe T, Matsumura T, Totsugawa T, Fujiwara T, Leboulch P, Tanaka N. Successful Retroviral Gene Transfer of Simian Virus 40 T Antigen and Herpes Simplex Virus-Thymidine Kinase into Human Hepatocytes 1. *Cell Transplant* 2001; **10**: 377-381 [PMID: 28886299 DOI: 10.3727/000000001783986585]

8 **Kobayashi N**, Noguchi H, Westerman KA, Watanabe T, Matsumura T, Totsugawa T, Fujiwara T, Leboulch P, Tanaka N. Cre/loxP-Based Reversible Immortalization of Human Hepatocytes 1. *Cell Transplant* 2001; **10**: 383-386 [PMID: 28886302 DOI: 10.3727/000000001783986558]

9 **Shahid JM**, Iwamuro M, Sasamoto H, Kubota Y, Seita M, Kawamoto H, Nakaji S, Noguchi H, Yamamoto K, Kobayashi N. Establishment of an immortalized porcine liver cell line JSNK-1 with retroviral transduction of SV40T. *Cell Transplant* 2010; **19**: 849-856 [PMID: 20955660 DOI: 10.3727/096368910X508979]

10 **Miyamoto Y**, Ikeuchi M, Noguchi H, Yagi T, Hayashi S. Spheroid Formation and Evaluation of Hepatic Cells in a Three-Dimensional Culture Device. *Cell Med* 2015; **8**: 47-56 [PMID: 26858908 DOI: 10.3727/215517915X689056]

11 **Miyamoto Y**, Ikeuchi M, Noguchi H, Yagi T, Hayashi S. Three-Dimensional In Vitro Hepatic Constructs Formed Using Combinatorial Tapered Stencil for Cluster Culture (TASCL) Device. *Cell Med* 2014; **7**: 67-74 [PMID: 26858895 DOI: 10.3727/215517914X685187]

12 **Kobayashi N**, Westerman KA, Tanaka N, Fox IJ, Leboulch P. A reversibly immortalized human hepatocyte cell line as a source of hepatocyte-based biological support. *Addict Biol* 2001; **6**: 293-300 [PMID: 11900607 DOI: 10.1080/13556210020077019]

13 **Kobayashi N**, Tanaka N. Engineering of Human Hepatocyte Lines for Cell Therapies in Humans: Prospects and Remaining Hurdles. *Cell Transplant* 2002; **11**: 417-420 [PMID: 28866930 DOI: 10.3727/000000002783985693]

14 **Sawada S**, Kinjo T, Makishi S, Tomita M, Arasaki A, Iseki K, Watanabe H, Kobayashi K, Sunakawa H, Iwamasa T, Mori N. Downregulation of citrin, a mitochondrial AGC, is associated with apoptosis of hepatocytes. *Biochem Biophys Res Commun* 2007; **364**: 937-944 [PMID: 18273444 DOI: 10.1016/j.bbrc.2007.10.105]

15 **Watanabe T**, Shibata N, Westerman KA, Okitsu T, Allain JE, Sakaguchi M, Totsugawa T, Maruyama M, Matsumura T, Noguchi H, Yamamoto S, Hikida M, Ohmori A, Reth M, Weber A, Tanaka N, Leboulch P, Kobayashi N. Establishment of immortalized human hepatic stellate scavenger cells to develop bioartificial livers. *Transplantation* 2003; **75**: 1873-1880 [PMID: 12811248 DOI: 10.1097/01.Tp.0000064621.50907.A6]

16 **Shibata N**, Watanabe T, Okitsu T, Sakaguchi M, Takesue M, Kunieda T, Omoto K, Yamamoto S, Tanaka N, Kobayashi N. Establishment of an immortalized human hepatic stellate cell line to develop antifibrotic therapies. *Cell Transplant* 2003; **12**: 499-507 [PMID: 12953924 DOI: 10.3727/000000003108747064]

17 **Higashi N**, Kohjima M, Fukushima M, Ohta S, Kotoh K, Enjoji M, Kobayashi N, Nakamuta M. Epigallocatechin-3-gallate, a green-tea polyphenol, suppresses Rho signaling in TWNT-4 human hepatic stellate cells. *J Lab Clin Med* 2005; **145**: 316-322 [PMID: 15976760 DOI: 10.1016/j.lab.2005.03.017]

18 **Nakamuta M**, Higashi N, Kohjima M, Fukushima M, Ohta S, Kotoh K, Kobayashi N, Enjoji M. Epigallocatechin-3-gallate, a polyphenol component of green tea, suppresses both collagen production and collagenase activity in hepatic stellate cells. *Int J Mol Med* 2005; **16**: 677-681 [PMID: 16142404 DOI: 10.3892/ijmm.16.4.677]

19 **Soto-Gutiérrez A**, Kobayashi N, Rivas-Carrillo JD, Navarro-Alvarez N, Zhao D, Okitsu T, Noguchi H, Basma H, Tabata Y, Chen Y, Tanaka K, Narushima M, Miki A, Ueda T, Jun HS, Yoon JW, Lebkowski J, Tanaka N, Fox IJ. Reversal of mouse hepatic failure using an implanted liver-assist device containing ES cell-derived hepatocytes. *Nat Biotechnol* 2006; **24**: 1412-1419 [PMID: 17086173 DOI: 10.1038/nbt1257]

20 **Soto-Gutierrez A**, Navarro-Alvarez N, Rivas-Carrillo JD, Chen Y, Yamatsuji T, Tanaka N, Kobayashi N. Differentiation of human embryonic stem cells to hepatocytes using deleted variant of HGF and poly-amino-urethane-coated nonwoven polytetrafluoroethylene fabric. *Cell Transplant* 2006; **15**: 335-341 [PMID: 16898227 DOI: 10.3727/000000006783981945]

21 **Soto-Gutiérrez A**, Navarro-Alvarez N, Zhao D, Rivas-Carrillo JD, Lebkowski J, Tanaka N, Fox IJ, Kobayashi N. Differentiation of mouse embryonic stem cells to hepatocyte-like cells by co-culture with human liver nonparenchymal cell lines. *Nat Protoc* 2007; **2**: 347-356 [PMID: 17406596 DOI: 10.1038/nprot.2007.18]

22 **Basma H**, Soto-Gutiérrez A, Yannam GR, Liu L, Ito R, Yamamoto T, Ellis E, Carson SD, Sato S, Chen Y, Muirhead D, Navarro-Alvarez N, Wong RJ, Roy-Chowdhury J, Platt JL, Mercer DF, Miller JD, Strom SC, Kobayashi N, Fox IJ. Differentiation and transplantation of human embryonic stem cell-derived hepatocytes. *Gastroenterology* 2009; **136**: 990-999 [PMID: 19026649 DOI: 10.1053/j.gastro.2008.10.047]

23 **Kobayashi N**, Okitsu T, Tanaka N. Cell choice for bioartificial livers. *Keio J Med* 2003; **52**: 151-157 [PMID: 14529147 DOI: 10.2302/kjm.52.151]

24 **Kobayashi N**, Okitsu T, Nakaji S, Tanaka N. Hybrid bioartificial liver: establishing a reversibly immortalized human hepatocyte line and developing a bioartificial liver for practical use. *J Artif Organs* 2003; **6**: 236-244 [PMID: 14691665 DOI: 10.1007/s10047-003-0235-7]

25 **Kobayashi N**. Life support of artificial liver: development of a bioartificial liver to treat liver failure. *J Hepatobiliary Pancreat Surg* 2009; **16**: 113-117 [PMID: 19110648 DOI: 10.1007/s00534-008-0022-1]

26 **Iwamuro M**, Shiraha H, Nakaji S, Furutani M, Kobayashi N, Takaki A, Yamamoto K. A preliminary study for constructing a bioartificial liver device with induced pluripotent stem cell-derived hepatocytes. *Biomed Eng Online* 2012; **11**: 93 [PMID: 23217363 DOI: 10.1186/1475-925X-11-93]

27 **Yonekawa Y**, Okitsu T, Wake K, Iwanaga Y, Noguchi H, Nagata H, Liu X, Kobayashi N, Matsumoto S. A new mouse model for intraportal islet transplantation with limited hepatic lobe as a graft site. *Transplantation* 2006; **82**: 712-715 [PMID: 16969298 DOI: 10.1097/01.tp.0000234906.29193.a6]

28 **Totsugawa T**, Yong C, Rivas-Carrillo JD, Soto-Gutierrez A, Navarro-Alvarez N, Noguchi H, Okitsu T, Westerman KA, Kohara M, Reth M, Tanaka N, Leboulch P, Kobayashi N. Survival of liver failure pigs by transplantation of reversibly immortalized human hepatocytes with Tamoxifen-mediated self-recombination. *J Hepatol* 2007; **47**: 74-82 [PMID: 17434229 DOI: 10.1016/j.jhep.2007.02.019]

29 **Yuasa T**, Yamamoto T, Rivas-Carrillo JD, Chen Y, Navarro-Alvarez N, Soto-Guiterrez A, Noguchi H, Matsumoto S, Tanaka N, Kobayashi N. Laparoscopy-assisted creation of a liver failure model in pigs. *Cell Transplant* 2008; **17**: 187-193 [PMID: 18468249 DOI: 10.3727/000000008783906973]

30 **Yukawa H**, Noguchi H, Oishi K, Takagi S, Hamaguchi M, Hamajima N, Hayashi S. Cell transplantation of adipose tissue-derived stem cells in combination with heparin attenuated acute liver failure in mice. *Cell Transplant* 2009; **18**: 611-618 [PMID: 19775523 DOI: 10.1177/096368970901805-617]

31 **Yamamoto T**, Navarro-Alvarez N, Soto-Gutierrez A, Yuasa T, Iwamuro M, Kubota Y, Seita M, Kawamoto H, Javed SM, Kondo E, Noguchi H, Kobayashi S, Nakaji S, Kobayashi N. Treatment of acute liver failure in mice by hepatocyte xenotransplantation. *Cell Transplant* 2010; **19**: 799-806 [PMID: 20573299 DOI: 10.3727/096368910X508915]

32 **Maruyama M**, Totsugawa T, Kunieda T, Okitsu T, Shibata N, Takesue M, Kurabayashi Y, Oshita M, Nakaji S, Kodama M, Tanaka N, Kobayashi N. Hepatocyte isolation and transplantation in the pig. *Cell Transplant* 2003; **12**: 593-598 [PMID: 14579927 DOI: 10.3727/000000003108747190]

33 **Chen Y**, Kobayashi N, Suzuki S, Soto-Gutierrez A, Rivas-Carrillo JD, Tanaka K, Navarro-Alvarez N, Fukazawa T, Narushima M, Miki A, Okitsu T, Amemiya H, Tanaka N. Transplantation of human hepatocytes cultured with deleted variant of hepatocyte growth factor prolongs the survival of mice with acute liver failure. *Transplantation* 2005; **79**: 1378-1385 [PMID: 15912107 DOI: 10.1097/01.TP.0000160813.37515.97]

34 **Wagers AJ**, Weissman IL. Plasticity of adult stem cells. *Cell* 2004; **116**: 639-648 [PMID: 15006347 DOI: 10.1016/S0092-8674(04)00208-9]

35 **Szöke K**, Brinchmann JE. Concise review: therapeutic potential of adipose tissue-derived angiogenic cells. *Stem Cells Transl Med* 2012; **1**: 658-667 [PMID: 23197872 DOI: 10.5966/sctm.2012-0069]

36 **Miyagi-Shiohira C**, Kurima K, Kobayashi N, Saitoh I, Watanabe M, Noguchi Y, Matsushita M, Noguchi H. Cryopreservation of Adipose-Derived Mesenchymal Stem Cells. *Cell Med* 2015; **8**: 3-7 [PMID: 26858903 DOI: 10.3727/215517915X689100]

37 **Seki A**, Sakai Y, Komura T, Nasti A, Yoshida K, Higashimoto M, Honda M, Usui S, Takamura M, Takamura T, Ochiya T, Furuichi K, Wada T, Kaneko S. Adipose tissue-derived stem cells as a regenerative therapy for a mouse steatohepatitis-induced cirrhosis model. *Hepatology* 2013; **58**: 1133-1142 [PMID: 23686813 DOI: 10.1002/hep.26470]

38 **Ullah I**, Subbarao RB, Rho GJ. Human mesenchymal stem cells - current trends and future prospective. *Biosci Rep* 2015; **35**: e00191 [PMID: 25797907 DOI: 10.1042/BSR20150025]

39 **Miyagi-Shiohira C**, Kobayashi N, Saitoh I, Watanabe M, Noguchi Y, Matsushita M, Noguchi H. Evaluation of Serum-Free, Xeno-Free Cryopreservation Solutions for Human Adipose-Derived Mesenchymal Stem Cells. *Cell Med* 2016; **9**: 15-20 [PMID: 28174671 DOI: 10.3727/215517916X693122]

40 **Nakashima Y**, Nahar S, Miyagi-Shiohira C, Kinjo T, Kobayashi N, Saitoh I, Watanabe M, Fujita J, Noguchi H. A Liquid Chromatography with Tandem Mass Spectrometry-Based Proteomic Analysis of Cells Cultured in DMEM 10% FBS and Chemically Defined Medium Using Human Adipose-Derived Mesenchymal Stem Cells. *Int J Mol Sci* 2018; **19**: 2042 [PMID: 30011845 DOI: 10.3390/ijms19072042]

41 **Nakashima Y,** Nahar S, Miyagi-Shiohira C, Kinjo T, Toyoda Z, Kobayashi N, Saitoh I, Watanabe M, Fujita J, Noguchi H. A liquid chromatography with tandem mass spectrometry-based proteomic analysis of the proteins secreted by human adipose-derived mesenchymal stem cells. *Cell Transplantation* 2018; In press

42 **Ashburner M**, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, Davis AP, Dolinski K, Dwight SS, Eppig JT, Harris MA, Hill DP, Issel-Tarver L, Kasarskis A, Lewis S, Matese JC, Richardson JE, Ringwald M, Rubin GM, Sherlock G. Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. *Nat Genet* 2000; **25**: 25-29 [PMID: 10802651 DOI: 10.1038/75556]

43 **Huntley RP**, Sawford T, Martin MJ, O'Donovan C. Understanding how and why the Gene Ontology and its annotations evolve: the GO within UniProt. *Gigascience* 2014; **3**: 4 [PMID: 24641996 DOI: 10.1186/2047-217X-3-4]

44 **Nakashima Y**, Miyagi-Shiohira C, Kobayashi N, Saitoh I, Watanabe M, Noguchi H. A proteome analysis of pig pancreatic islets and exocrine tissue by liquid chromatography with tandem mass spectrometry. *Islets* 2017; **9**: 159-176 [PMID: 29099648 DOI: 10.1080/19382014.2017.1389826]

45 **Polson J**, Lee WM; American Association for the Study of Liver Disease. AASLD position paper: the management of acute liver failure. *Hepatology* 2005; **41**: 1179-1197 [PMID: 15841455 DOI: 10.1002/hep.20703]

46 **Hautekeete ML**, Geerts A. The hepatic stellate (Ito) cell: its role in human liver disease. *Virchows Arch* 1997; **430**: 195-207 [PMID: 9099976 DOI: 10.1007/BF01324802]

47 **Zimmers TA**, McKillop IH, Pierce RH, Yoo JY, Koniaris LG. Massive liver growth in mice induced by systemic interleukin 6 administration. *Hepatology* 2003; **38**: 326-334 [PMID: 12883476 DOI: 10.1053/jhep.2003.50318]

48 **Fausto N**, Campbell JS, Riehle KJ. Liver regeneration. *Hepatology* 2006; **43**: S45-S53 [PMID: 16447274 DOI: 10.1002/hep.20969]

49 **Soto-Gutierrez A**, Navarro-Alvarez N, Caballero-Corbalan J, Tanaka N, Kobayashi N. Endoderm induction for hepatic and pancreatic differentiation of ES cells. *Acta Med Okayama* 2008; **62**: 63-68 [PMID: 18464881 DOI: 10.18926/AMO/30961]

50 **Hamada E**, Ebi N, Miyagi-Shiohira C, Tamaki Y, Nakashima Y, Kobayashi N, Saitoh I, Watanabe M, Kinjo T, Noguchi H. Comparison Between Modified Extracellular-Type Trehalose-Containing Kyoto Solution and University of Wisconsin Solution in 18-Hour Pancreas Preservation for Islet Transplantation. *Pancreas* 2018; **47**: e46-e47 [PMID: 29985851 DOI: 10.1097/MPA.0000000000001104]

51 **Nakashima Y,** Miyagi-Shiohira C, Ebi N, Hamada E, Tamaki Y, Kuwae K, Kobayashi N, Saitoh I, Watanabe M, Kinjo T, Noguchi H. A Comparison of Pancreatic Islet Purification using Iodixanol with University of Wisconsin Solution and with Na-lactobionate and Histidine Solution. *Cell Med* 2018; **10**:1-7 [DOI: 10.1177/2155179018775071]

52 **Miyagi-Shiohira C,** Nakashima Y, Ebi N, Hamada E, Tamaki Y, Kuwae K, Kobayashi N, Saitoh I, Watanabe M, Kinjo T, Noguchi H. Comparison of tissue loading before and after the creation of a continuous density gradient in porcine islet purification. *Cell Med* 2018; **10**: 1-7 [DOI: 10.1177/2155179018781343]

53 **Miyagi-Shiohira C**, Kobayashi N, Saitoh I, Watanabe M, Noguchi Y, Matsushita M, Noguchi H. Comparison of Purification Solutions With Different Osmolality for Porcine Islet Purification. *Cell Med* 2016; **9**: 53-59 [PMID: 28174675 DOI: 10.3727/215517916X693140]

54 **Takesue M**, Maruyama M, Shibata N, Kunieda T, Okitsu T, Sakaguchi M, Totsugawa T, Kosaka Y, Arata A, Ikeda H, Matsuoka J, Oyama T, Kodama M, Ohmoto K, Yamamoto S, Kurabayashi Y, Yamamoto I, Tanaka N, Kobayashi N. Maintenance of cold-preserved porcine hepatocyte function with UW solution and ascorbic acid-2 glucoside. *Cell Transplant* 2003; **12**: 599-606 [PMID: 14579928 DOI: 10.3727/000000003108747208]

55 **Kunieda T**, Maruyama M, Okitsu T, Shibata N, Takesue M, Totsugawa T, Kosaka Y, Arata T, Kobayashi K, Ikeda H, Oshita M, Nakaji S, Ohmoto K, Yamamoto S, Kurabayashi Y, Kodama M, Tanaka N, Kobayashi N. Cryopreservation of primarily isolated porcine hepatocytes with UW solution. *Cell Transplant* 2003; **12**: 607-616 [PMID: 14579929 DOI: 10.3727/000000003108747217]

56 **Arata T**, Okitsu T, Fukazawa T, Ikeda H, Kobayashi K, Yong C, Kosaka Y, Narushima M, Matsuoka J, Yamamoto I, Tanaka N, Lakey JR, Kobayashi N. Maintenance of glucose-sensitive insulin secretion of cryopreserved human islets with University of Wisconsin solution and ascorbic acid-2 glucoside. *Artif Organs* 2004; **28**: 529-536 [PMID: 15153144 DOI: 10.1111/j.1525-1594.2004.07296.x]

57 **Nahar S,** Nakashima Y, Miyagi-Shiohira C, Kinjo T, Toyoda Z, Kobayashi N, Saitoh I, Watanabe M, Fujita J, Noguchi H. Tissue-derived mesenchymal stem cells using the university of wisconsin solution and hank’s balanced salt solution. *Stem Cells Int* 2018; **2018**: 1625464 [DOI: 10.1155/2018/1625464]

58 **de Jong IEM**, van Leeuwen OB, Lisman T, Gouw ASH, Porte RJ. Repopulating the biliary tree from the peribiliary glands. *Biochim Biophys Acta* 2018; **1864**: 1524-1531 [PMID: 28778591 DOI: 10.1016/j.bbadis.2017.07.037]

59 **Wu T**, Wu S, Ouyang G. Periostin: a new extracellular regulator of obesity-induced hepatosteatosis. *Cell Metab* 2014; **20**: 562-564 [PMID: 25295785 DOI: 10.1016/j.cmet.2014.09.005]

60 **Lu Y**, Liu X, Jiao Y, Xiong X, Wang E, Wang X, Zhang Z, Zhang H, Pan L, Guan Y, Cai D, Ning G, Li X. Periostin promotes liver steatosis and hypertriglyceridemia through downregulation of PPARα. *J Clin Invest* 2014; **124**: 3501-3513 [PMID: 25003192 DOI: 10.1172/JCI74438]

61 **Zhou Z**, Xu MJ, Gao B. Hepatocytes: a key cell type for innate immunity. *Cell Mol Immunol* 2016; **13**: 301-315 [PMID: 26685902 DOI: 10.1038/cmi.2015.97]

62 **De Minicis S**, Rychlicki C, Agostinelli L, Saccomanno S, Trozzi L, Candelaresi C, Bataller R, Millán C, Brenner DA, Vivarelli M, Mocchegiani F, Marzioni M, Benedetti A, Svegliati-Baroni G. Semaphorin 7A contributes to TGF-β-mediated liver fibrogenesis. *Am J Pathol* 2013; **183**: 820-830 [PMID: 23850082 DOI: 10.1016/j.ajpath.2013.05.030]

63 **Kluwe J**, Pradere JP, Gwak GY, Mencin A, De Minicis S, Osterreicher CH, Colmenero J, Bataller R, Schwabe RF. Modulation of hepatic fibrosis by c-Jun-N-terminal kinase inhibition. *Gastroenterology* 2010; **138**: 347-359 [PMID: 19782079 DOI: 10.1053/j.gastro.2009.09.015]

64 **Poulos JE**, Weber JD, Bellezzo JM, Di Bisceglie AM, Britton RS, Bacon BR, Baldassare JJ. Fibronectin and cytokines increase JNK, ERK, AP-1 activity, and transin gene expression in rat hepatic stellate cells. *Am J Physiol* 1997; **273**: G804-G811 [PMID: 9357821]

65 **Hong IH**, Park SJ, Goo MJ, Lee HR, Park JK, Ki MR, Kim SH, Lee EM, Kim AY, Jeong KS. JNK1 and JNK2 regulate α-SMA in hepatic stellate cells during CCl4 -induced fibrosis in the rat liver. *Pathol Int* 2013; **63**: 483-491 [PMID: 24134609 DOI: 10.1111/pin.12094]

66 **Noguchi H**, Nakai Y, Ueda M, Masui Y, Futaki S, Kobayashi N, Hayashi S, Matsumoto S. Activation of c-Jun NH2-terminal kinase (JNK) pathway during islet transplantation and prevention of islet graft loss by intraportal injection of JNK inhibitor. *Diabetologia* 2007; **50**: 612-619 [PMID: 17225125 DOI: 10.1007/s00125-006-0563-2]

67 **Noguchi H**, Nakai Y, Matsumoto S, Kawaguchi M, Ueda M, Okitsu T, Iwanaga Y, Yonekawa Y, Nagata H, Minami K, Masui Y, Futaki S, Tanaka K. Cell permeable peptide of JNK inhibitor prevents islet apoptosis immediately after isolation and improves islet graft function. *Am J Transplant* 2005; **5**: 1848-1855 [PMID: 15996231 DOI: 10.1111/j.1600-6143.2005.00985.x]

68 **Noguchi H**. Activation of c-Jun NH2-terminal kinase during islet isolation. *Endocr J* 2007; **54**: 169-176 [PMID: 17124365 DOI: 10.1507/endocrj.KR-87]

69 **Noguchi H**, Miyagi-Shiohira C, Nakashima Y, Ebi N, Hamada E, Tamaki Y, Kuwae K, Kobayashi N, Saitoh I, Watanabe M. Modified cell-permeable JNK inhibitors efficiently prevents islet apoptosis and improves the outcome of islet transplantation. *Sci Rep* 2018; **8**: 11082 [PMID: 30038242 DOI: 10.1038/s41598-018-29481-9]

70 **Kotoh K**, Nakamuta M, Kohjima M, Fukushima M, Morizono S, Kobayashi N, Enjoji M, Nawata H. Arg-Gly-Asp (RGD) peptide ameliorates carbon tetrachloride-induced liver fibrosis via inhibition of collagen production and acceleration of collagenase activity. *Int J Mol Med* 2004; **14**: 1049-1053 [PMID: 15547672 DOI: 10.3892/ijmm.14.6.1049]

71 **Fukushima M**, Nakamuta M, Kohjima M, Kotoh K, Enjoji M, Kobayashi N, Nawata H. Fasudil hydrochloride hydrate, a Rho-kinase (ROCK) inhibitor, suppresses collagen production and enhances collagenase activity in hepatic stellate cells. *Liver Int* 2005; **25**: 829-838 [PMID: 15998434 DOI: 10.1111/j.1478-3231.2005.01142.x]

72 **Yukawa H**, Watanabe M, Kaji N, Okamoto Y, Tokeshi M, Miyamoto Y, Noguchi H, Baba Y, Hayashi S. Monitoring transplanted adipose tissue-derived stem cells combined with heparin in the liver by fluorescence imaging using quantum dots. *Biomaterials* 2012; **33**: 2177-2186 [PMID: 22192539 DOI: 10.1016/j.biomaterials.2011.12.009]

73 **Koilan S**, Hamilton D, Baburyan N, Padala MK, Weber KT, Guntaka RV. Prevention of liver fibrosis by triple helix-forming oligodeoxyribonucleotides targeted to the promoter region of type I collagen gene. *Oligonucleotides* 2010; **20**: 231-237 [PMID: 20818932 DOI: 10.1089/oli.2010.0244]

74 **Liu XY**, Liu RX, Hou F, Cui LJ, Li CY, Chi C, Yi E, Wen Y, Yin CH. Fibronectin expression is critical for liver fibrogenesis in vivo and in vitro. *Mol Med Rep* 2016; **14**: 3669-3675 [PMID: 27572112 DOI: 10.3892/mmr.2016.5673]

75 **Li Y**, Turpin CP, Wang S. Role of thrombospondin 1 in liver diseases. *Hepatol Res* 2017; **47**: 186-193 [PMID: 27492250 DOI: 10.1111/hepr.12787]

76 **Lafdil F**, Chobert MN, Couchie D, Brouillet A, Zafrani ES, Mavier P, Laperche Y. Induction of Gas6 protein in CCl4-induced rat liver injury and anti-apoptotic effect on hepatic stellate cells. *Hepatology* 2006; **44**: 228-239 [PMID: 16799993 DOI: 10.1002/hep.21237]

77 **Bárcena C**, Stefanovic M, Tutusaus A, Joannas L, Menéndez A, García-Ruiz C, Sancho-Bru P, Marí M, Caballeria J, Rothlin CV, Fernández-Checa JC, de Frutos PG, Morales A. Gas6/Axl pathway is activated in chronic liver disease and its targeting reduces fibrosis via hepatic stellate cell inactivation. *J Hepatol* 2015; **63**: 670-678 [PMID: 25908269 DOI: 10.1016/j.jhep.2015.04.013]

78 **Bottazzi B**, Inforzato A, Messa M, Barbagallo M, Magrini E, Garlanda C, Mantovani A. The pentraxins PTX3 and SAP in innate immunity, regulation of inflammation and tissue remodelling. *J Hepatol* 2016; **64**: 1416-1427 [PMID: 26921689 DOI: 10.1016/j.jhep.2016.02.029]

79 **Wilhelm A**, Aldridge V, Haldar D, Naylor AJ, Weston CJ, Hedegaard D, Garg A, Fear J, Reynolds GM, Croft AP, Henderson NC, Buckley CD, Newsome PN. CD248/endosialin critically regulates hepatic stellate cell proliferation during chronic liver injury via a PDGF-regulated mechanism. *Gut* 2016; **65**: 1175-1185 [PMID: 26078290 DOI: 10.1136/gutjnl-2014-308325]

80 **Heinrichs D**, Knauel M, Offermanns C, Berres ML, Nellen A, Leng L, Schmitz P, Bucala R, Trautwein C, Weber C, Bernhagen J, Wasmuth HE. Macrophage migration inhibitory factor (MIF) exerts antifibrotic effects in experimental liver fibrosis via CD74. *Proc Natl Acad Sci U S A* 2011; **108**: 17444-17449 [PMID: 21969590 DOI: 10.1073/pnas.1107023108]

81 **Colletti LM**, Green M, Burdick MD, Kunkel SL, Strieter RM. Proliferative effects of CXC chemokines in rat hepatocytes in vitro and in vivo. *Shock* 1998; **10**: 248-257 [PMID: 9788656 DOI: 10.1097/00024382-199810000-00004]

82 **Tacke F**, Zimmermann HW, Trautwein C, Schnabl B. CXCL5 plasma levels decrease in patients with chronic liver disease. *J Gastroenterol Hepatol* 2011; **26**: 523-529 [PMID: 21332547 DOI: 10.1111/j.1440-1746.2010.06436.x]

83 **Elpek GÖ**. Angiogenesis and liver fibrosis. *World J Hepatol* 2015; **7**: 377-391 [PMID: 25848465 DOI: 10.4254/wjh.v7.i3.377]

84 **Amarapurkar AD**, Amarapurkar DN, Vibhav S, Patel ND. Angiogenesis in chronic liver disease. *Ann Hepatol* 2007; **6**: 170-173 [PMID: 17786144]

85 **Fernández M**, Semela D, Bruix J, Colle I, Pinzani M, Bosch J. Angiogenesis in liver disease. *J Hepatol* 2009; **50**: 604-620 [PMID: 19157625 DOI: 10.1016/j.jhep.2008.12.011]

86 **Huber K**, Christ G, Wojta J, Gulba D. Plasminogen activator inhibitor type-1 in cardiovascular disease. Status report 2001. *Thromb Res* 2001; **103 Suppl 1**: S7-19 [PMID: 11567664 DOI: 10.1016/S0049-3848(01)00293-6]

87 **Wu J**, Strawn TL, Luo M, Wang L, Li R, Ren M, Xia J, Zhang Z, Ma W, Luo T, Lawrence DA, Fay WP. Plasminogen activator inhibitor-1 inhibits angiogenic signaling by uncoupling vascular endothelial growth factor receptor-2-αVβ3 integrin cross talk. *Arterioscler Thromb Vasc Biol* 2015; **35**: 111-120 [PMID: 25378411 DOI: 10.1161/ATVBAHA.114.304554]

88 **Shang H**, Liu X, Guo H. Knockdown of Fstl1 attenuates hepatic stellate cell activation through the TGF‑β1/Smad3 signaling pathway. *Mol Med Rep* 2017; **16**: 7119-7123 [PMID: 28901425 DOI: 10.3892/mmr.2017.7445]

89 **Lindner V**, Wang Q, Conley BA, Friesel RE, Vary CP. Vascular injury induces expression of periostin: implications for vascular cell differentiation and migration. *Arterioscler Thromb Vasc Biol* 2005; **25**: 77-83 [PMID: 15514205 DOI: 10.1161/01.ATV.0000149141.81230.c6]

90 **Kessenbrock K**, Plaks V, Werb Z. Matrix metalloproteinases: regulators of the tumor microenvironment. *Cell* 2010; **141**: 52-67 [PMID: 20371345 DOI: 10.1016/j.cell.2010.03.015]

91 **Duarte S**, Baber J, Fujii T, Coito AJ. Matrix metalloproteinases in liver injury, repair and fibrosis. *Matrix Biol* 2015; **44-46**: 147-156 [PMID: 25599939 DOI: 10.1016/j.matbio.2015.01.004]

92 **Smalling RL**, Delker DA, Zhang Y, Nieto N, McGuiness MS, Liu S, Friedman SL, Hagedorn CH, Wang L. Genome-wide transcriptome analysis identifies novel gene signatures implicated in human chronic liver disease. *Am J Physiol Gastrointest Liver Physiol* 2013; **305**: G364-G374 [PMID: 23812039 DOI: 10.1152/ajpgi.00077.2013]

93 **Reed MJ**, Koike T, Sadoun E, Sage EH, Puolakkainen P. Inhibition of TIMP1 enhances angiogenesis in vivo and cell migration in vitro. *Microvasc Res* 2003; **65**: 9-17 [PMID: 12535866 DOI: 10.1016/S0026-2862(02)00026-2]

94 **Timpl R**, Sasaki T, Kostka G, Chu ML. Fibulins: a versatile family of extracellular matrix proteins. *Nat Rev Mol Cell Biol* 2003; **4**: 479-489 [PMID: 12778127 DOI: 10.1038/nrm1130]

95 **Wang R**, Zhang YW, Chen LB. Aberrant promoter methylation of FBLN-3 gene and clinicopathological significance in non-small cell lung carcinoma. *Lung Cancer* 2010; **69**: 239-244 [PMID: 19913326 DOI: 10.1016/j.lungcan.2009.10.009]

96 **Silvestre JS**, Théry C, Hamard G, Boddaert J, Aguilar B, Delcayre A, Houbron C, Tamarat R, Blanc-Brude O, Heeneman S, Clergue M, Duriez M, Merval R, Lévy B, Tedgui A, Amigorena S, Mallat Z. Lactadherin promotes VEGF-dependent neovascularization. *Nat Med* 2005; **11**: 499-506 [PMID: 15834428 DOI: 10.1038/nm1233]

97 **Uchiyama A**, Yamada K, Ogino S, Yokoyama Y, Takeuchi Y, Udey MC, Ishikawa O, Motegi S. MFG-E8 regulates angiogenesis in cutaneous wound healing. *Am J Pathol* 2014; **184**: 1981-1990 [PMID: 24838098 DOI: 10.1016/j.ajpath.2014.03.017]

98 **Nakashima Y**, Miyagi-Shiohira C, Noguchi H, Omasa T. The Healing Effect of Human Milk Fat Globule-EGF Factor 8 Protein (MFG-E8) in A Rat Model of Parkinson's Disease. *Brain Sci* 2018; **8**: 167 [PMID: 30200351 DOI: 10.3390/brainsci8090167]

99 **Sanyal AJ**, Brunt EM, Kleiner DE, Kowdley KV, Chalasani N, Lavine JE, Ratziu V, McCullough A. Endpoints and clinical trial design for nonalcoholic steatohepatitis. *Hepatology* 2011; **54**: 344-353 [PMID: 21520200 DOI: 10.1002/hep.24376]

**P-Reviewer:** Grawish ME, Labusca S, Song YH, Tanabe S

**S-Editor:** Wang JL **L-Editor: E-Editor:**

**Specialty type:** Cell and tissue engineering

**Country of origin:** Japan

**Peer-review report classification**


Grade A (Excellent): A, A

Grade B (Very good): B


Grade C (Good): C

Grade D (Fair): 0


Grade E (Poor): 0




**Figure 1 Schematic diagram of a normal liver tissue model.** The liver is a digestive organ that filters and detoxifies blood from the digestive tract. It also produces proteins, such as albumin, and synthesizes cholesterol and bile. The functional portion of the liver tissue is organized into hexagonal columns called liver lobules. Each liver lobule contains hundreds of individual liver cells (hepatocytes) and a large central vein. Lobular portal triads, which contain branches from the hepatic portal vein, hepatic artery and bile duct, are located at the points of the hexagonal lobule. Blood from the branches of the hepatic artery joins the blood of the hepatic vein branches, forming hepatic sinusoids. Hepatic sinusoids are lined with specialized cells called Kupffer cells, which help collect debris and detoxify the blood. All hepatic sinusoids in the liver lobule drain into the central vein. Adjacent lobules are separated by a thin fibrous septa. Images were obtained from BIODIGITAL HUMAN 3.0 (https://human.biodigital.com/index.html) (BioDigital, Broadway, NY, USA).



**Figure 2 Schematic diagram of a liver cirrhosis tissue model.** The functional portion of the liver tissue is organized into hexagonal columns called liver lobules. Each liver lobule contains hundreds of individual liver cells (hepatocytes). In healthy liver tissue, adjacent lobules are separated by thin fibrous septa. However, liver cirrhosis involves thickening of the fibrous septa that separate lobules, and the deposition of fat. As a result, the blood flow in the lobules is disturbed and hepatocyte necrosis occurs. Also, the fibrous septa that separate the lobules transform the lobules and produce pseudolobules. Although it has a wide variety of causes, liver cirrhosis is most commonly caused by chronic alcohol abuse, chronic hepatitis, and nonalcoholic fatty liver disease. Images were obtained from BIODIGITAL HUMAN 3.0 (https://human.biodigital.com/index.html) (BioDigital, Broadway, NY, USA).



**Figure 3 Culture supernatant concentrate significantly improved the symptoms of acute liver failure caused by the administration of CCL4.** Micrographic images of H&E staining (A, left panel), TUNEL assay (A, middle panels) and tissue immunostaining of Ki67 (A, right panel) of liver specimens. Microscopic images of liver specimens 20 hours after the administration of PBS (upper panels) and CM (lower panels) via the mouse tail vein. Scale bar = 200 μm. Fragmented DNA generated in the process of apoptosis can be detected by the TUNEL (TdT-mediated UTP nick end labeling) method. Ki67 protein present in the nucleus of cells in G1, S, G2 and M cycles (cell growth phase) was detected using immunostaining to identify cells in the growth phase in liver tissue. It was also used to count the number of positively stained cells in images of TUNNEL-stained sections (× 400). The numbers of positively stained cells in the PBS and CM groups were 14.00 ± 4.54 and 8.25 ± 5.57, respectively (*n* = 4; *P* = 0.19). The numbers of cells with positively stained nuclei on images of Ki67-stained sections (× 400) were also counted. The numbers of cells with positively stained nuclei in the PBS and CM groups were 9.25 ± 7.61 and 116.25 ± 3.06, respectively (*n* = 4; *P* < 0.01).



**Figure 4 Adipose-derived mesenchymal stem cells improved symptoms of tissue fibrosis in cirrhosis caused by the administration of CCL4.** Micrographic image of Azan staining of liver specimens. Azan staining is a fibrous connective tissue staining method that differentiates collagen fibers and muscle fibers. The fibrous connective tissue in the tissue section was stained blue. Microscopic images of the liver specimens 20 hours after the administration of PBS (upper panels) and adipose-derived mesenchymal stem cells (ADSC) (lower panels) via the mouse tail vein. In the ADSC administration group, fibrosis and pseudolobule formation were ameliorated. Microscopic images (×100 - 400) of the same tissue section. Scale bar = 150 - 600 μm.

**Table 1 Relationship between immunomodulatory protein secreted by adipose-derived mesenchymal stem cells and liver cirrhosis**



**Table 2 Relationship between angiogenesis protein secreted by adipose-derived mesenchymal stem cells and liver cirrhosis**

****